National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda · Sep 19, 2026
Sotagliflozin
By Hoofnagle JH
Sotagliflozin is a small molecule, dual inhibitor of the sodium-glucose cotransporters 1 and 2 that is used to reduce the risk of cardiovascular death and heart failure events in adults with heart failure or with type 2 diabetes and chronic kidney disease. Sotagliflozin has not been associated with serum aminotransferase elevations during therapy or with clinically apparent liver injury.